Table 1 Parameter definitions and values associated with the different WHO regions

Inc^a

Incidence (new cases/100,000/year)

275 (239–314)

27 (25–29)

116 (86–149)

36 (33–38)

246 (167–339)

86 (78–94)

142 (119–166)

a^a

rate of MDR/RR-TB among new TB-cases (%)

3 (1.2-4.9)

2.9 (1.6-4.2)

4.1 (3–5.1)

16 (11–20)

2.6 (2.3-3)

5.1 (3–7.2)

3.9 (2.7-5.1)

b^b

drug sensitivity testing coverage in new TB-cases (%)

21

29

2

44

5.1

8.8

24

c^b

treatment success rates for new DS-TB cases (%)

81

76

91

76

79

92

83

d^b

treatment success rates for MDR/RR-TB cases (%)

54

55

68

52

49

57

52

e^c

treatment success rate for MDR/RR-TB treated with first-line regimen (%)

0-20

0-20

0-20

0-20

0-20

0-20

0-20

f^c

risk of drug-resistance amplification for a DS-TB patient failing therapy (%)

10-20

10-20

10-20

10-20

10-20

10-20

10-20

h^b

proportion of detected MDR/RR-TB cases that start on second-line regimen (%)

68.64

75.16

82.5

100

90.81

76.14

94.6

m^b

death proportion during treatment for DS-TB and MDR/RR-TB patients (%)

5.76

6.95

1.84

7.85

3.52

2.05

3.84

k^b

death proportion during treatment for MDR/RR-TB (%)

20.58

8.22

16.03

15.61

20.59

9.51

16.84